Company intelligence / Profile preview

BugSense Diagnostics

Munich, Bavaria, Germanylinkedin.com ↗

Ownership: Private
Employees: ~8
Development stage: Preclinical

Overview

BugSense has developed a patented paper-based diagnostic patch for rapid UTI and antibiotic resistance testing. The system uses colorimetric readout analyzed by an AI-powered smartphone app to identify pathogens and their concentration as well as common resistances. It aims to provide lab-quality results without the need for specialized equipment or personnel. Clinical performance data are not detailed in public sources but the technology claims accuracy comparable to standard culture devices with much faster turnaround time.

Therapeutic areas: Infectious Diseases
Modalities: Paper-based diagnostic deviceAI-based image analysis software
Industry: Metabolite Diagnostics

Partnerships

Technical University of Munich (TUM) via Oliver Hayden's group

Beyond the preview

Go deeper on BugSense Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BugSense Diagnostics.

Explore the full profile